Menu Search
Equities

SkinBioTherapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5KW:STU

SkinBioTherapeutics PLC

Actions
  • Price (EUR)0.054
  • Today's Change0.004 / 8.00%
  • Shares traded0.00
  • 1 Year change-75.89%
  • Beta1.5312
Data delayed at least 15 minutes, as of Feb 17 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Cash flow in GBPView more

In 2025, SkinBioTherapeutics PLC increased its cash reserves by 496.76%, or 3.98m. Cash Flow from Financing totalled 6.83m or 147.36% of revenues. In addition the company used 1.24m for operations while cash used for investing totalled 1.62m.
Cash flow per share-0.0012
Price/Cash flow per share--
Book value per share0.0364
Tangible book value per share0.0198
More ▼

Balance sheet in GBPView more

SkinBioTherapeutics PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.29% of the market capitalization can be attributed to its 4.78m and debt could be paid in full if management chose.
Current ratio4.84
Quick ratio4.29
Total debt/total equity0.1055
Total debt/total capital0.0954
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.